Michael Risk, MD PhD

Assistant Professor, Department of Urology

Michael Risk

Contact Info

michael.risk@va.gov, mcrisk@umn.edu

Administrative Assistant Name
Liz Mayock

Administrative Phone
612-626-7099

Additional Locations

Practices:

Assistant Professor, Department of Urology


University of Illinois, Chicago

University of Washington Medical Center

Fellowship in Urologic Oncology, Indiana University School of Medicine

Ph.D., Physiology and Biophysics, University of Illinois at Chicago, 2003.

M.D., University of Illinois at Chicago, 2003

Summary

Dr. Risk’s clinical focus is on the surgical treatment of urologic malignancies, including cancers of the bladder, kidney, prostate and testis. He also has a clinical interest in the medical and surgical management of male urinary incontinence and erectile dysfunction. His research interests include investigation of the mechanisms of carcinogenesis and disease progression in prostate and bladder cancer.

Expertise

  • Bladder Cancer
  • Kidney Cancer
  • Penile Cancer
  • Prostate Cancer
  • Testis Cancer
  • Male Urinary Incontinence
  • Erectile Dysfunction

Research

Publications

Wright JL, Risk MC, Hotaling J, Lin DW. Effect of Collecting Duct Histology on Outcomes in Renal Cell Carcinoma J Urol 182 (6): 2595-2600 (2009).

Campbell JB, Lendvay TS, Risk MC, Vemulakonda VM, Kirsch AJ, Cheng E, Cisek LJ, Koyle MA. Endoscopic treatment of symptomatic refluxing renal transplant ureterneocystotomies in children. Pediatr Transplant 14(2): 212-215 (2010).

Risk MC, Masterson T. Intratubular germ cell neoplasms of the testis and bilateral testicular tumors: clinical significance and management options. Indian J Urol 26(1):103-110 (2010).

Risk MC, Coleman I, Dumpit R, Hawley S, Littman AJ, Kristal AB, LeMeur N, Gentleman RC, Knudsen BS, Nelson PS, Lin DW. Differential Gene Expression in Normal Prostate Epithelium of Men with and without Prostate Cancer: Evidence for a Prostate Cancer Field Effect. Clin Cancer Res16(22):5414-23 (2010)

Risk MC, Foster RS. Current status of and controversies regarding post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. Expert Rev Anticancer Ther 11(1):95-106 (2011).